Evidence map›Paper›PMID 42234284›Full record

ArticleMolecular biology reports2026

Correction: Heparanase (HPSE) genetic variants as prognostic indicators in ovarian cancer: evidence from discovery and validation cohorts.

Inês Guerra de Melo, Valéria Tavares, Joana Savva-Bordalo, Mariana Rei, Joana Liz-Pimenta, Deolinda Pereira, Rui Medeiros

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Inês Guerra de MeloMolecular Oncology and Viral Pathology Group, Department of Pathology and Laboratory Medicine/RISE - Associate Laboratory (Health Research Network), IPO Porto Research Centre (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, 4200-072, Portugal.
Valéria TavaresMolecular Oncology and Viral Pathology Group, Department of Pathology and Laboratory Medicine/RISE - Associate Laboratory (Health Research Network), IPO Porto Research Centre (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, 4200-072, Portugal.
Joana Savva-BordaloDepartment of Medical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, 4200-072, Portugal.
Mariana ReiDepartment of Gynaecology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, 4200-072, Portugal.
Joana Liz-PimentaFaculty of Medicine, University of Porto (FMUP), Porto, 4200-072, Portugal.
Deolinda PereiraDepartment of Medical Oncology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, 4200-072, Portugal.
Rui MedeirosMolecular Oncology and Viral Pathology Group, Department of Pathology and Laboratory Medicine/RISE - Associate Laboratory (Health Research Network), IPO Porto Research Centre (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Porto, 4200-072, Portugal. ruimedei@ipoporto.min-saude.pt.ORCID http://orcid.org/0000-0003-3010-8373

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42234284
PMCPMC13233646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.